Clinical Trials Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 16, 2023; 11(26): 6105-6121
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6105
Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients
Sahar Kmal Hegazy, Samar Tharwat, Ahmed Hosny Hassan
Sahar Kmal Hegazy, Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta 31511, Egypt
Samar Tharwat, Rheumatology and Immunology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura university, Mansoura 35511, Egypt
Ahmed Hosny Hassan, Clinical Pharmacy Department, Mansoura University Hospital, Mansoura 35511, Egypt
Author contributions: Hegazy SK designed research, and supervised research; Tharwat S supervised research; Hassan AH designed and performed research, wrote the paper, and analyzed data.
Institutional review board statement: The study was reviewed and approved by the Research ethics committee, ministry of health, Egypt, Faculty of Medicine, Mansour University, and the Research ethics committee, faculty of medicine, Tanta University.
Clinical trial registration statement: this clinical trial is registered in clinicaltrial.gov with ID: NCT05502081 https://clinicaltrials.gov/ct2/show/NCT05502081.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Supplementary data are available at: https://drive.google.com/drive/folders/1X1dDQwW9vBvusutwMbeebUjN8jJqYxsh?usp=sharing.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ahmed H. Hassan, BPharm, PharmD, Pharmacist, Researcher, Clinical Pharmacy, Mansoura University Hospital, No. 2 Street, El-gomhoria, Mansoura 35511, Egypt. ahmedony26@gmail.com
Received: May 16, 2023
Peer-review started: May 16, 2023
First decision: July 18, 2023
Revised: July 18, 2023
Accepted: August 17, 2023
Article in press: August 17, 2023
Published online: September 16, 2023
Processing time: 114 Days and 21.2 Hours
Core Tip

Core Tip: This research can benefit the coronavirus disease 2019 (COVID-19) patients by determining the most appropriate antiviral drug according to the case. This study may change the protocol of treatment of COVID-19 patients. Casirivimab and imdevimab achieve better clinical outcomes than remdesivir and favipiravir.